Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2016

Open Access 01-12-2016 | Review

Survivin: a unique target for tumor therapy

Authors: Himani Garg, Prerna Suri, Jagdish C. Gupta, G. P. Talwar, Shweta Dubey

Published in: Cancer Cell International | Issue 1/2016

Login to get access

Abstract

Survivin is the smallest member of the Inhibitor of apoptosis (IAP) family of proteins, involved in inhibition of apoptosis and regulation of cell cycle. These functional attributes make Survivin a unique protein exhibiting divergent functions i.e. regulating cell proliferation and cell death. Expression pattern of Survivin is also distinctive; it is prominently expressed during embryonal development, absent in most normal, terminally differentiated tissues but upregulated in a variety of human cancers. Expression of Survivin in tumours correlates with not only inhibition of apoptosis and a decreased rate of cell death, but also resistance to chemotherapy and aggressiveness of tumours. Therefore, Survivin is an important target for cancer vaccines and therapeutics. Survivin has also been found to be prominently expressed on both human and embryonic stem cells and many somatic stem cell types indicating its yet unexplored role in stem cell generation and maintenance. Overall, Survivin emerges as a molecule with much wider role in cellular homeostasis. This review will discuss various aspects of Survivin biology and its role in regulation of apoptosis, cell division, chemo-resistance and tumour progression. Various molecular and immunotherapeutic approaches targeting Survivin will also be discussed.
Literature
1.
Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 1995;83(7):1243–52.PubMedCrossRef
2.
Duckett CS, Nava VE, Gedrich RW, Clem RJ, Van Dongen JL, Gilfillan MC, Shiels H, Hardwick JM, Thompson CB. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J. 1996;15(11):2685–94.PubMedPubMedCentral
3.
Rajcan-Separovic E, Liston P, Lefebvre C, Korneluk RG. Assignment of human inhibitor of apoptosis protein (IAP) genes xiap, hiap-1, and hiap-2 to chromosomes Xq25 and 11q22-q23 by fluorescence in situ hybridization. Genomics. 1996;37(3):404–6.PubMedCrossRef
4.
Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, Farahani R, McLean M, Ikeda JE, MacKenzie A, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature. 1996;379(6563):349–53.PubMedCrossRef
5.
Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917–21.PubMedCrossRef
6.
Hauser HP, Bardroff M, Pyrowolakis G, Jentsch S. A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. J Cell Biol. 1998;141(6):1415–22.PubMedPubMedCentralCrossRef
7.
Salvesen GS, Duckett CS. IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol. 2002;3(6):401–10.PubMedCrossRef
8.
LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene. 2008;27(48):6252–75.PubMedCrossRef
9.
10.
Birnbaum MJ, Clem RJ, Miller LK. An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. J Virol. 1994;68(4):2521–8.PubMedPubMedCentral
11.
Kelly R, Lopez-Chavez A, Citrin D, Janik JE, Morris JC. Impacting tumor-cell fate by targeting the inhibitor of apoptosis protein Survivin. Mol Cancer. 2011;10:35.PubMedPubMedCentralCrossRef
12.
Deveraux QL, Reed JC. IAP family proteins–suppressors of apoptosis. Genes Dev. 1999;13(3):239–52.PubMedCrossRef
13.
Deveraux QL, Stennicke HR, Salvesen GS, Reed JC. Endogenous inhibitors of caspases. J Clin Immunol. 1999;19(6):388–98.PubMedCrossRef
14.
Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in. Mol Cancer Ther. 2006;5:1087–98.PubMedCrossRef
15.
Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 2004;64(20):7183–90.PubMedCrossRef
16.
Harvey AJ, Soliman H, Kaiser WJ, Miller LK. Anti- and pro-apoptotic activities of baculovirus and Drosophila IAPs in an insect cell line. Cell Death Differ. 1997;4(8):733–44.PubMedCrossRef
17.
Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 1997;16(23):6914–25.PubMedPubMedCentralCrossRef
18.
Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388(6639):300–4.PubMedCrossRef
19.
Blankenship JW, Varfolomeev E, Goncharov T, Fedorova AV, Kirkpatrick DS, Izrael-Tomasevic A, Phu L, Arnott D, Aghajan M, Zobel K, et al. Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1). Biochem J. 2009;417(1):149–60.PubMedCrossRef
20.
Gyrd-Hansen M, Darding M, Miasari M, Santoro MM, Zender L, Xue W, Tenev T, da Fonseca PC, Zvelebil M, Bujnicki JM, et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol. 2008;10(11):1309–17.PubMedPubMedCentralCrossRef
21.
Mahotka C, Liebmann J, Wenzel M, Suschek C, Schmitt M, Gabbert H. Differential subcellular localization of functionally. Cell Death Differ. 2002;9:1334–42.PubMedCrossRef
22.
23.
Sampath J, Pelus LM. Alternative splice variants of Survivin as potential targets in cancer. Curr Drug Discov Technol. 2007;4(3):174–91.PubMedCrossRef
24.
de Necochea-Campio R, Chen C-S, Mirshahidi S, Howard FD, Wall NR. Clinico-pathologic relevance of Survivin splice variant expression. Cancer Lett. 2013;339:167–74.CrossRef
25.
Necochea-Campion R, Chen CS, Mirshahidi S, Howard FD, Wall NR. Clinico-pathologic relevance of Survivin splice variant expression in cancer. Cancer Lett. 2013;339(2):167–74.PubMedPubMedCentralCrossRef
26.
Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos FI, Marousi S, Stavropoulos M, Koutras AK, Scopa CD, Kalofonos HP. The Survivin -31 snp in human colorectal cancer correlates with Survivin splice variant expression and improved overall survival. Anal Cell Pathol (Amst). 2010;33(5):177–89.CrossRef
27.
Suga K, Yamamoto T, Yamada Y, Miyatake S, Nakagawa T, Tanigawa N. Correlation between transcriptional expression of Survivin isoforms and clinicopathological findings in human colorectal carcinomas. Oncol Rep. 2005;13(5):891–7.PubMed
28.
Li F. Role of Survivin and its splice variants in tumorigenesis. Br J Cancer. 2005;92:212–6.PubMed
29.
Doucette T, Latha K, Yang Y, Fuller GN, Rao A, Rao G. Survivin transcript variant 2 drives angiogenesis and malignant progression in proneural gliomas. Neuro Oncol. 2014;16(9):1220–8.PubMedPubMedCentralCrossRef
30.
Engels K, Knauer SK, Metzler D, Simf C, Struschka O, Bier C, Mann W, Kovacs AF, Stauber RH. Dynamic intracellular Survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol. 2007;211(5):532–40.PubMedCrossRef
31.
32.
Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial Survivin inhibits apoptosis and promotes tumorigenesis. J Clin Investig. 2004;114(8):1117–27.PubMedPubMedCentralCrossRef
33.
Khan S, Bennit HF, Wall NR. The emerging role of exosomes in Survivin secretion. Histol Histopathol. 2015;30(1):43–50.PubMed
34.
Valenzuela MMA, Ferguson Bennit HR, Gonda A, Diaz Osterman CJ, Hibma A, Khan S, Wall NR. Exosomes secreted from human cancer cell lines contain inhibitors of apoptosis (IAP). Cancer Microenviron. 2015;8(2):65–73.PubMedPubMedCentralCrossRef
35.
Khan S, Aspe JR, Asumen MG, Almaguel F, Odumosu O, Acevedo-Martinez S, De Leon M, Langridge WH, Wall NR. Extracellular, cell-permeable Survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br J Cancer. 2009;100(7):1073–86.PubMedPubMedCentralCrossRef
36.
Khan S, Jutzy JM, Aspe JR, McGregor DW, Neidigh JW, Wall NR. Survivin is released from cancer cells via exosomes. Apoptosis Int J Program Cell Death. 2011;16(1):1–12.CrossRef
37.
Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR. Plasma-derived exosomal Survivin, a plausible biomarker for early detection of prostate cancer. PLoS One. 2012;7(10):e46737.PubMedPubMedCentralCrossRef
38.
Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC, Altieri DC. Pleiotropic cell-division defects and apoptosis induced by interference with Survivin function. Nat Cell Biol. 1999;1(8):461–6.PubMedCrossRef
39.
Ruchaud S, Carmena M, Earnshaw WC. The chromosomal passenger complex: one for all and all for one. Cell. 2007;131(2):230–1.PubMedCrossRef
40.
Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol. 2007;8(10):798–812.PubMedCrossRef
41.
Roland SH, Mann W, Shirley KK. Nuclear and cytoplasmic Survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 2007;67:5999–6002.CrossRef
42.
Kitagawa M, Lee SH. The chromosomal passenger complex (CPC) as a key orchestrator of orderly mitotic exit and cytokinesis. Front Cell Dev Biol. 2015;3:14.PubMedPubMedCentralCrossRef
43.
Vader G, Kauw JJ, Medema RH, Lens SM. Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep. 2006;7(1):85–92.PubMedCrossRef
44.
Lens SM, Vader G, Medema RH. The case for Survivin as mitotic regulator. Curr Opin Cell Biol. 2006;18(6):616–22.PubMedCrossRef
45.
Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. IAP-family protein Survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58(23):5315–20.PubMed
46.
Kobayashi K, Hatano M, Otaki M, Ogasawara T, Tokuhisa T. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci USA. 1999;96(4):1457–62.PubMedPubMedCentralCrossRef
47.
Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and Survivin-2B: two novel splice variants of the apoptosis inhibitor Survivin with different antiapoptotic properties. Cancer Res. 1999;59(24):6097–102.PubMed
48.
Altieri DC. The molecular basis and potential role of Survivin in cancer diagnosis and therapy. Trends Mol Med. 2001;7(12):542–7.PubMedCrossRef
49.
Adams RR, Carmena M, Earnshaw WC. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol. 2001;11(2):49–54.PubMedCrossRef
50.
Cheung CHA, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, Huang YC, Chen SH, Chang JY. Survivin—biology and potential as a therapeutic target in oncology. OncoTargets Ther. 2013;6:1453–62.CrossRef
51.
52.
Johnson ME, Howerth EW. Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol. 2004;41(6):599–607.PubMedCrossRef
53.
Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14:5000–5.PubMedCrossRef
54.
55.
Song Z, Yao X, Wu M. Direct interaction between Survivin and Smac/DIABLO is essential for the anti-apoptotic activity of Survivin during taxol-induced apoptosis. J Biol Chem. 2003;278(25):23130–40.PubMedCrossRef
56.
57.
Fernandez JG, Rodriguez DA, Valenzuela M, Calderon C, Urzua U, Munroe D, Rosas C, Lemus D, Diaz N, Wright MC, et al. Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K/Akt enhanced beta-catenin/Tcf-Lef dependent transcription. Mol Cancer. 2014;13:209.PubMedPubMedCentralCrossRef
58.
Wang P, Zhen H, Zhang J, Zhang W, Zhang R, Cheng X, Guo G, Mao X, Wang J, Zhang X. Survivin promotes glioma angiogenesis through vascular endothelial growth factor and basic fibroblast growth factor in vitro and in vivo. Mol Carcinog. 2012;51(7):586–95.PubMedCrossRef
59.
Li QX, Zhao J, Liu JY, Jia LT, Huang HY, Xu YM, Zhang Y, Zhang R, Wang CJ, Yao LB, et al. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther. 2006;5(7):860–6.PubMedCrossRef
60.
Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for Survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA. 2002;99(7):4349–54.PubMedPubMedCentralCrossRef
61.
Virrey JJ, Guan S, Li W, Schonthal AH, Chen TC, Hofman FM. Increased Survivin expression confers chemoresistance to tumor-associated endothelial cells. Am J Pathol. 2008;173(2):575–85.PubMedPubMedCentralCrossRef
62.
McKenzie JA, Grossman D. Role of the apoptotic and mitotic regulator Survivin in melanoma. Anticancer Res. 2012;32(2):397–404.PubMed
63.
64.
McKenzie JA, Liu T, Jung JY, Jones BB, Ekiz HA, Welm AL, Grossman D. Survivin promotion of melanoma metastasis requires upregulation of alpha5 integrin. Carcinogenesis. 2013;34(9):2137–44.PubMedPubMedCentralCrossRef
65.
66.
Chu XY, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, Xue LJ, Liu XB, Mo XB. Overexpression of Survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol. 2012;105(6):520–8.PubMedCrossRef
67.
Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor LY, Pollack A, Zhang Y, Zietman AL, Shipley WU, et al. Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Phys. 2010;78(4):1095–103.PubMedPubMedCentralCrossRef
68.
Fukuda S, Mantel CR, Pelus LM. Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways. Blood. 2004;103(1):120–7.PubMedCrossRef
69.
Feng R, Zhou S, Liu Y, Song D, Luan Z, Dai X, Li Y, Tang N, Wen J, Li L. Sox2 protects neural stem cells from apoptosis via up-regulating Survivin expression. Biochem J. 2013;450(3):459–68.PubMedCrossRef
70.
Nakaya T, Ogawa S, Manabe I, Tanaka M, Sanada M, Sato T, Taketo MM, Nakao K, Clevers H, Fukayama M, et al. KLF5 regulates the integrity and oncogenicity of intestinal stem cells. Cancer Res. 2014;74(10):2882–91.PubMedCrossRef
71.
Mull AN, Klar A, Navara CS. Differential localization and high expression of SURVIVIN splice variants in human embryonic stem cells but not in differentiated cells implicate a role for SURVIVIN in pluripotency. Stem cell Res. 2014;12(2):539–49.PubMedCrossRef
72.
Li C, Yan Y, Ji W, Bao L, Qian H, Chen L, Wu M, Chen H, Li Z, Su C. OCT4 positively regulates Survivin expression to promote cancer cell proliferation and leads to poor prognosis in esophageal squamous cell carcinoma. PLoS One. 2012;7(11):e49693.PubMedPubMedCentralCrossRef
73.
Fukuda S, Abe M, Onishi C, Taketani T, Purevsuren J, Yamaguchi S, Conway EM, Pelus LM. Survivin selectively modulates genes deregulated in human leukemia stem cells. J Oncol. 2011;2011:946936.PubMedCrossRef
74.
Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL, Choo KH. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol. 2000;10(21):1319–28.PubMedCrossRef
75.
Fukuda S, Hoggatt J, Singh P, Abe M, Speth JM, Hu P, Conway EM, Nucifora G, Yamaguchi S, Pelus LM. Survivin modulates genes with divergent molecular functions and regulates proliferation of hematopoietic stem cells through Evi-1. Leukemia. 2015;29(2):433–40.PubMedCrossRef
76.
Okada H, Bakal C, Shahinian A, Elia A, Wakeham A, Suh WK, Duncan GS, Ciofani M, Rottapel R, Zuniga-Pflucker JC, et al. Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med. 2004;199(3):399–410.PubMedPubMedCentralCrossRef
77.
Song J, So T, Cheng M, Tang X, Croft M. Sustained Survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity. 2005;22(5):621–31.PubMedCrossRef
78.
Miletic AV, Jellusova J, Cato MH, Lee CR, Baracho GV, Conway EM, Rickert RC. Essential role for Survivin in the proliferative expansion of progenitor and mature B cells. J Immunol. 2016;196(5):2195–204.PubMedCrossRef
79.
Leung CG, Xu Y, Mularski B, Liu H, Gurbuxani S, Crispino JD. Requirements for Survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med. 2007;204(7):1603–11.PubMedPubMedCentralCrossRef
80.
Gurbuxani S, Xu Y, Keerthivasan G, Wickrema A, Crispino JD. Differential requirements for Survivin in hematopoietic cell development. Proc Natl Acad Sci USA. 2005;102(32):11480–5.PubMedPubMedCentralCrossRef
81.
McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154–8.PubMedPubMedCentral
82.
83.
Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208(10):1989–2003.PubMedPubMedCentralCrossRef
84.
85.
86.
Pardoll D. Cancer and the immune system: basic Concepts and targets for intervention. Semin Oncol. 2015;42(4):523–38.PubMedCrossRef
87.
Andersen MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-associated antigen Survivin. Clin Cancer Res. 2007;13(20):5991–4.PubMedCrossRef
88.
Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by Survivin gene targeting. J Biol Chem. 1998;273(18):11177–82.PubMedCrossRef
89.
Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res. 2000;91(11):1204–9.PubMedCrossRef
90.
Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, et al. Analysis of human transcriptomes. Nat Genet. 1999;23(4):387–8.PubMedCrossRef
91.
Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by Survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58(22):5071–4.PubMed
92.
Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule Survivin and recurrence of bladder cancer. New Engl J Med. 1999;341(6):452–3.PubMedCrossRef
93.
Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, Survivin, in human melanoma. J Invest Dermatol. 1999;113(6):1076–81.PubMedCrossRef
94.
Grossman D, McNiff JM, Li F, Altieri DC. Expression of the apoptosis inhibitor, Survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest. 1999;79(9):1121–6.PubMed
95.
Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG, Rieber EP. Generation of Survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 2000;60(17):4845–9.PubMed
96.
Hofmann UB, Voigt H, Andersen MH, Straten PT, Becker JC, Eggert AO. Identification and characterization of Survivin-derived H-2 Kb-restricted CTL epitopes. Eur J Immunol. 2009;39(5):1419–24.PubMedCrossRef
97.
Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein Survivin in cancer patients. Cancer Res. 2001;61(3):869–72.PubMed
98.
Siegel S, Steinmann J, Schmitz N, Stuhlmann R, Dreger P, Zeis M. Identification of a Survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes. Leukemia. 2004;18(12):2046–7.PubMedCrossRef
99.
Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersen MH. Identification of novel Survivin-derived CTL epitopes. Cancer Biol Ther. 2004;3(2):173–9.PubMedCrossRef
100.
Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. HLA-B35-restricted immune responses against Survivin in cancer patients. Int J Cancer. 2004;108(6):937–41.PubMedCrossRef
101.
Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against Survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001;61(16):5964–8.PubMed
102.
Zhu K, Qin H, Cha SC, Neelapu SS, Overwijk W, Lizee GA, Abbruzzese JL, Hwu P, Radvanyi L, Kwak LW, et al. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine. 2007;25(46):7955–61.PubMedCrossRef
103.
Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer. 2007;57(3):365–72.PubMedPubMedCentralCrossRef
104.
Honma I, Kitamura H, Torigoe T, Takahashi A, Tanaka T, Sato E, Hirohashi Y, Masumori N, Tsukamoto T, Sato N. Phase I clinical study of anti-apoptosis protein Survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother. 2009;58(11):1801–7.PubMedCrossRef
105.
Miyazaki A, Kobayashi J, Torigoe T, Hirohashi Y, Yamamoto T, Yamaguchi A, Asanuma H, Takahashi A, Michifuri Y, Nakamori K, et al. Phase I clinical trial of Survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci. 2011;102(2):324–9.PubMedCrossRef
106.
Tsuruma T, Hata F, Torigoe T, Furuhata T, Idenoue S, Kurotaki T, Yamamoto M, Yagihashi A, Ohmura T, Yamaguchi K, et al. Phase I clinical study of anti-apoptosis protein, Survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med. 2004;2(1):19.PubMedPubMedCentralCrossRef
107.
Tsuruma T, Iwayama Y, Ohmura T, Katsuramaki T, Hata F, Furuhata T, Yamaguchi K, Kimura Y, Torigoe T, Toyota N, et al. Clinical and immunological evaluation of anti-apoptosis protein, Survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med. 2008;6:24.PubMedPubMedCentralCrossRef
108.
Tanaka T, Kitamura H, Inoue R, Nishida S, Takahashi-Takaya A, Kawami S, Torigoe T, Hirohashi Y, Tsukamoto T, Sato N, et al. Potential survival benefit of anti-apoptosis protein: Survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer–results from phase I clinical trials. Clin Dev Immunol. 2013;2013:262967.PubMedPubMedCentral
109.
Becker JC, Andersen MH, Hofmeister-Muller V, Wobser M, Frey L, Sandig C, Walter S, Singh-Jasuja H, Kampgen E, Opitz A, et al. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother. 2012;61(11):2091–103.PubMedPubMedCentralCrossRef
110.
Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein AF, et al. Immunologic response to the Survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother. 2014;63(4):381–94.PubMedCrossRef
111.
Riedmann EM. Ovarian cancer vaccine candidate DPX-Survivac: positive interim results from phase 1. Hum Vaccin Immunother. 2012;8(12):1743.CrossRef
112.
Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, Schreibelt G, Mus R, De Wilt JH, Haanen JB, et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res. 2013;73(1):19–29.PubMedCrossRef
113.
Tanaka M, Butler MO, Ansen S, Imataki O, Berezovskaya A, Nadler LM, Hirano N. Induction of HLA-DP4-restricted anti-Survivin Th1 and Th2 responses using an artificial antigen-presenting cell. Clin Cancer Res. 2011;17(16):5392–401.PubMedPubMedCentralCrossRef
114.
Widenmeyer M, Griesemann H, Stevanovic S, Feyerabend S, Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, et al. Promiscuous Survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. Int J Cancer. 2012;131(1):140–9.PubMedCrossRef
115.
Wang XF, Kerzerho J, Adotevi O, Nuyttens H, Badoual C, Munier G, Oudard S, Tu S, Tartour E, Maillere B. Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen Survivin in healthy donors and cancer patients. J Immunol. 2008;181(1):431–9.PubMedCrossRef
116.
Ohtake J, Ohkuri T, Togashi Y, Kitamura H, Okuno K, Nishimura T. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. Immunol Lett. 2014;161(1):20–30.PubMedCrossRef
117.
Sharma RK, Yolcu ES, Srivastava AK, Shirwan H. CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models. PLoS One. 2013;8(9):e73145.PubMedPubMedCentralCrossRef
118.
Hoffmann PR, Panigada M, Soprana E, Terry F, Bandar IS, Napolitano A, Rose AH, Hoffmann FW, Ndhlovu LC, Belcaid M, et al. Preclinical development of HIvax: human Survivin highly immunogenic vaccines. Hum Vaccin Immunother. 2015;11(7):1585–95.PubMedPubMedCentralCrossRef
119.
Rakshit S, Ponnusamy M, Papanna S, Saha B, Ahmed A, Nandi D. Immunotherapeutic efficacy of Mycobacterium indicus pranii in eliciting anti-tumor T cell responses: critical roles of IFNgamma. Int J Cancer. 2012;130(4):865–75.PubMedCrossRef
120.
Kumar P, John V, Marathe S, Das G, Bhaskar S. Mycobacterium indicus pranii induces dendritic cell activation, survival, and Th1/Th17 polarization potential in a TLR-dependent manner. J Leukoc Biol. 2015;97(3):511–20.PubMedCrossRef
121.
Guo K, Tang JP, Tan CP, Wang H, Zeng Q. Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. Cancer Biol Ther. 2008;7(5):750–7.PubMedCrossRef
122.
Guo K, Li J, Tang JP, Tan CP, Hong CW, Al-Aidaroos AQ, Varghese L, Huang C, Zeng Q. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med. 2011;3(99):99ra85.PubMedCrossRef
123.
Hong CW, Zeng Q. Tapping the treasure of intracellular oncotargets with immunotherapy. FEBS Lett. 2014;588(2):350–5.PubMedCrossRef
124.
Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, Conrad K, Rieber EP. Antibody response to the tumor-associated inhibitor of apoptosis protein Survivin in cancer patients. Cancer Res. 2000;60(7):1815–7.PubMed
125.
Nagaraj S, Pisarev V, Kinarsky L, Sherman S, Muro-Cacho C, Altieri DC, Gabrilovich DI. Dendritic cell-based full-length Survivin vaccine in treatment of experimental tumors. J Immunother. 2007;30(2):169–79.PubMedCrossRef
126.
Bertino P, Panigada M, Soprana E, Bianchi V, Bertilaccio S, Sanvito F, Rose AH, Yang H, Gaudino G, Hoffmann PR, et al. Fowlpox-based Survivin vaccination for malignant mesothelioma therapy. Int J Cancer. 2013;133(3):612–23.PubMedPubMedCentralCrossRef
127.
Srivastava AK, Sharma RK, Yolcu ES, Ulker V, MacLeod K, Dinc G, Shirwan H. Prime-boost vaccination with SA-4-1BBL costimulatory molecule and Survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner. PLoS One. 2012;7(11):e48463.PubMedPubMedCentralCrossRef
128.
Madireddi S, Schabowsky RH, Srivastava AK, Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-gamma. PLoS One. 2012;7(8):e42459.PubMedPubMedCentralCrossRef
129.
Ishizaki H, Manuel ER, Song GY, Srivastava T, Sun S, Diamond DJ, Ellenhorn JD. Modified vaccinia Ankara expressing Survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother. 2011;60(1):99–109.PubMedCrossRef
130.
Xiang R, Mizutani N, Luo Y, Chiodoni C, Zhou H, Mizutani M, Ba Y, Becker JC, Reisfeld RA. A DNA vaccine targeting Survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 2005;65(2):553–61.PubMed
131.
Kameshima H, Tsuruma T, Torigoe T, Takahashi A, Hirohashi Y, Tamura Y, Tsukahara T, Ichimiya S, Kanaseki T, Iwayama Y, et al. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, Survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci. 2011;102(6):1181–7.PubMedCrossRef
132.
Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, et al. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology. 2015;4(8):e1026529.PubMedPubMedCentralCrossRef
133.
Trepiakas R, Berntsen A, Hadrup SR, Bjorn J, Geertsen PF, Straten PT, Andersen MH, Pedersen AE, Soleimani A, Lorentzen T, et al. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy. 2010;12(6):721–34.PubMedCrossRef
134.
Xiao M, Wang J, Lin Z, Lu Y, Li Z, White SW, Miller DD, Li W. Design, synthesis and structure-activity relationship studies of novel Survivin inhibitors with potent anti-proliferative properties. PLoS One. 2015;10(6):e0129807.PubMedPubMedCentralCrossRef
135.
Xiao M, Li W. Recent advances on small-molecule Survivin inhibitors. Curr Med Chem. 2015;22(9):1136–46.CrossRef
136.
Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, et al. YM155, a novel small-molecule Survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007;67(17):8014–21.PubMedCrossRef
137.
Na YS, Yang SJ, Kim SM, Jung KA, Moon JH, Shin JS, Yoon DH, Hong YS, Ryu MH, Lee JL, et al. YM155 induces EGFR suppression in pancreatic cancer cells. PLoS One. 2012;7(6):e38625.PubMedPubMedCentralCrossRef
138.
Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A, Shamsili S. Multicenter phase II trial of YM155, a small-molecule suppressor of Survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol. 2009;27(27):4481–6.PubMedCrossRef
139.
Chang CC, Heller JD, Kuo J, Huang RC. Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and Survivin expression. Proc Natl Acad Sci USA. 2004;101(36):13239–44.PubMedPubMedCentralCrossRef
140.
Khanna N, Dalby R, Tan M, Arnold S, Stern J, Frazer N. Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol Oncol. 2007;107(3):554–62.PubMedCrossRef
141.
Shi X, Wang D, Ding K, Lu Z, Jin Y, Zhang J, Pan J. GDP366, a novel small molecule dual inhibitor of Survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Cancer Biol Ther. 2010;9(8):640–50.PubMedCrossRef
142.
Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F. A novel small molecule FL118 that selectively inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS One. 2012;7(9):e45571.PubMedPubMedCentralCrossRef
143.
Talbot DC, Ranson M, Davies J, Lahn M, Callies S, Andre V, Kadam S, Burgess M, Slapak C, Olsen AL, et al. Tumor Survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res. 2010;16(24):6150–8.PubMedCrossRef
144.
Choi KS, Lee TH, Jung MH. Ribozyme-mediated cleavage of the human Survivin mRNA and inhibition of antiapoptotic function of Survivin in MCF-7 cells. Cancer Gene Ther. 2003;10(2):87–95.PubMedCrossRef
145.
Karami H, Baradaran B, Esfahani A, Estiar MA, Naghavi-Behzad M, Sakhinia M, Sakhinia E. siRNA-mediated silencing of Survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells. Asian Pac J Cancer Prev. 2013;14(12):7719–24.PubMedCrossRef
146.
Paduano F, Villa R, Pennati M, Folini M, Binda M, Daidone MG, Zaffaroni N. Silencing of Survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther. 2006;5(1):179–86.PubMedCrossRef
147.
Zhang R, Wang T, Li KN, Qin WW, Chen R, Wang K, Jia LT, Zhao J, Wen WH, Meng YL, et al. A Survivin double point mutant has potent inhibitory effect on the growth of hepatocellular cancer cells. Cancer Biol Ther. 2008;7(4):547–54.PubMedCrossRef
148.
Cheung CH, Sun X, Kanwar JR, Bai JZ, Cheng L, Krissansen GW. A cell-permeable dominant-negative Survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-alpha therapy. Cancer Cell Int. 2010;10:36.PubMedPubMedCentralCrossRef
Metadata
Title
Survivin: a unique target for tumor therapy
Authors
Himani Garg
Prerna Suri
Jagdish C. Gupta
G. P. Talwar
Shweta Dubey
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2016
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-016-0326-1

Other articles of this Issue 1/2016

Cancer Cell International 1/2016 Go to the issue

Review

Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy

Primary research

Alpha-synuclein contributes to malignant progression of human meningioma via the Akt/mTOR pathway

Primary research

Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line

Primary research

Antibiotics inhibit sphere-forming ability in suspension culture

Primary research

A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition

Primary research

Positive effect of HPV status on prognostic value of blood lymphocyte-to-monocyte ratio in advanced cervical carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits